Biotech | August 09, 2021
AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
This work has been published in the journal ‘ACS applied materials and interface’
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
